The U.S. Securities and Exchange Commission sued Decision Diagnostics Corp. and its chief executive for allegedly misleading investors by promising the biotechnology company could test for COVID-19 with a finger-prick of blood and provide accurate results in less than one minute.
In a complaint filed on Thursday in Manhattan federal court, the SEC said Chief Executive Keith Berman made materially false statements between March and June about what he claimed was his company’s blood testing kit, and its efforts to obtain Food and Drug Administration approval for its emergency use.
The SEC said all the California-based company had at the time was “a theoretical concept that had not yet materialized into a product,” and that Berman’s misstatements led to surges in Decision Diagnostics’ stock price and trading volume.
Decision Diagnostics did not immediately respond to requests for comment.
(Reporting by Jonathan Stempel in New York; Editing by Will Dunham)
Filing: SEC v Keith Berman and Decision Diagnostics Corp.
Related:
- Investors’ Suit Alleges Firm Inflated Stock with Misleading Claims About Its Covid Test
- Royal Caribbean Cruise Line Hit with Shareholder Lawsuit Over Coronavirus
Topics Lawsuits
Was this article valuable?
Here are more articles you may enjoy.
Oaktree’s Deal to Buy A-Cap Insurer Crumbles, Spawning New Talks 
All in the Family: Husband, Wife and Daughter Indicted for Insurance Fraud and Bribery 
Former Trident Reciprocal CEO Ordered to Pay $468K in Attorney and Arbitrator Fees 
KCC Says Isaias Insured Losses to Be $3 Billion; AM Best Calls Storm an Earnings Event 
